Applied DNA Sciences Announces $7.5 Million Financing
News Jul 23, 2013
At the initial closing, the Company received gross proceeds of $2,000,000 in exchange for restricted common stock priced at $0.187/share (Initial Closing).
Pursuant to the Agreement, the investor is obligated to invest an additional $5,500,000 in the Company on the date a registration statement providing for the resale of the securities issued is declared effective by the Securities and Exchange Commission ("Second Closing"). This closing will be done at $1,000 per share of preferred stock with a conversion price the lesser of market value or $0.187/share. The investor is limited to 9.9% ownership at any given point in time. The investor is in a "passive" position and will not occupy a Board position. The preferred stock is subject to conversion into common stock at the Company's option following the effectiveness of the registration statement and automatically converts after one year.
Warrants issued as a part of this financing could contribute up to an additional $9.75 million in funds to the company if exercised for cash. The Warrants also have a cashless exercise feature. Warrants would be exercised at a strike price equal to $0.2431 per share which is a 30% premium to the original purchase price of $0.187/share. The Company intends to file a registration statement covering the common stock and common stock underlying the warrants and preferred stock. The Company agreed to pay Crede an investment fee equal to $100,000 at the Initial Closing and $265,000 at the Second Closing.
More detailed information on this financing can be found in the Form 8-K filed with the SEC.
This financing will allow APDN to continue to scale its operations and broaden its product line to meet the demand of a growing number of contracts in electronics and other verticals, continue to hire top sales, operational, and scientific talent, leverage valuable assets acquired from RedWeb Technologies, and further expand the company's market share in Europe.
Dr. James A. Hayward, President and CEO of Applied DNA Sciences said, "We have built our recent successes on an ability to deliver high-security, high-quality solutions. As we grow, we intend to build on this momentum."
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019
8th World Congress on Green Chemistry and Technology
Feb 18 - Feb 20, 2019